[go: up one dir, main page]

CL2012001668A1 - Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. - Google Patents

Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.

Info

Publication number
CL2012001668A1
CL2012001668A1 CL2012001668A CL2012001668A CL2012001668A1 CL 2012001668 A1 CL2012001668 A1 CL 2012001668A1 CL 2012001668 A CL2012001668 A CL 2012001668A CL 2012001668 A CL2012001668 A CL 2012001668A CL 2012001668 A1 CL2012001668 A1 CL 2012001668A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
hydrochloric acid
epoc
ethanol
filling
Prior art date
Application number
CL2012001668A
Other languages
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2012001668A1 publication Critical patent/CL2012001668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/10—Adding propellants in solid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y un cosolvente, en donde la composición contiene ácido clorhídrico 1m en el intervalo de 0,005-1,0 ug/ul; kit que la comprende; y su uso para el tratamiento o la profilaxis de enfermedades respiratorias tal como epoc.
CL2012001668A 2009-12-23 2012-06-19 Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. CL2012001668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09015980 2009-12-23

Publications (1)

Publication Number Publication Date
CL2012001668A1 true CL2012001668A1 (es) 2012-12-07

Family

ID=42046446

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001668A CL2012001668A1 (es) 2009-12-23 2012-06-19 Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.

Country Status (31)

Country Link
US (5) US20110150783A1 (es)
EP (1) EP2515854B1 (es)
JP (1) JP5800829B2 (es)
KR (1) KR101747474B1 (es)
CN (1) CN102665680B (es)
AU (2) AU2010334858A1 (es)
CA (1) CA2785317C (es)
CL (1) CL2012001668A1 (es)
CO (1) CO6551734A2 (es)
CY (1) CY1115109T1 (es)
DK (1) DK2515854T3 (es)
EA (1) EA021604B1 (es)
ES (1) ES2464520T3 (es)
GE (1) GEP20166479B (es)
HR (1) HRP20140550T1 (es)
IL (1) IL220534A0 (es)
MA (1) MA33821B1 (es)
MX (1) MX340264B (es)
MY (1) MY156950A (es)
NZ (1) NZ600789A (es)
PE (1) PE20121467A1 (es)
PH (1) PH12012501063A1 (es)
PL (1) PL2515854T3 (es)
PT (1) PT2515854E (es)
RS (1) RS53355B (es)
SG (1) SG181870A1 (es)
SI (1) SI2515854T1 (es)
TN (1) TN2012000261A1 (es)
UA (1) UA106098C2 (es)
WO (1) WO2011076842A2 (es)
ZA (1) ZA201204613B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
CN115989032A (zh) 2020-07-31 2023-04-18 化学研究有限公司 用于吸入施用的组合疗法
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
JP2023546025A (ja) 2020-10-09 2023-11-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧定量吸入器のための医薬製剤
CA3257044A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATION FOR PRESSURIZED DOSING AEROSOL

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DE69324161T2 (de) 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1372608B1 (de) * 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
ATE465712T1 (de) 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
CA2510043A1 (en) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2009051818A1 (en) 2007-10-18 2009-04-23 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102695496B (zh) * 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) * 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
CA2807406C (en) * 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.

Also Published As

Publication number Publication date
NZ600789A (en) 2014-09-26
CA2785317A1 (en) 2011-06-30
WO2011076842A3 (en) 2011-12-01
US20150306026A1 (en) 2015-10-29
MX2012006879A (es) 2012-07-04
US11590074B2 (en) 2023-02-28
US12357568B2 (en) 2025-07-15
DK2515854T3 (da) 2014-05-26
PH12012501063A1 (en) 2013-02-04
EP2515854A2 (en) 2012-10-31
ES2464520T3 (es) 2014-06-03
UA106098C2 (uk) 2014-07-25
EP2515854B1 (en) 2014-03-19
CA2785317C (en) 2018-02-27
MY156950A (en) 2016-04-15
PL2515854T3 (pl) 2014-08-29
US20110150783A1 (en) 2011-06-23
CN102665680A (zh) 2012-09-12
SG181870A1 (en) 2012-07-30
RS53355B (sr) 2014-10-31
EA021604B1 (ru) 2015-07-30
CY1115109T1 (el) 2016-12-14
KR20120120160A (ko) 2012-11-01
KR101747474B1 (ko) 2017-06-14
JP2013515695A (ja) 2013-05-09
ZA201204613B (en) 2013-09-25
BR112012015336A2 (pt) 2016-03-15
HRP20140550T1 (hr) 2014-07-18
PE20121467A1 (es) 2012-11-07
CO6551734A2 (es) 2012-10-31
JP5800829B2 (ja) 2015-10-28
MA33821B1 (fr) 2012-12-03
SI2515854T1 (sl) 2014-07-31
US10806701B2 (en) 2020-10-20
US20210000738A1 (en) 2021-01-07
GEP20166479B (en) 2016-05-25
HK1174568A1 (en) 2013-06-14
AU2010334858A1 (en) 2012-07-12
EA201290374A1 (ru) 2013-01-30
MX340264B (es) 2016-07-04
TN2012000261A1 (en) 2013-12-12
IL220534A0 (en) 2012-08-30
AU2016234894B2 (en) 2018-02-22
US20250262151A1 (en) 2025-08-21
CN102665680B (zh) 2014-07-30
AU2016234894A1 (en) 2016-10-13
PT2515854E (pt) 2014-05-27
WO2011076842A2 (en) 2011-06-30
US20230157951A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
CL2012001668A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.
CL2012001705A1 (es) Composición farmacéutica que comprende a) bromuro de glicopirronio, b) formoterol o fumarato de formoterol y c) dipropionato de beclometasona, disueltos en hfa134a y etanol (entre 10-15 % p/p), hcl 1m entre 0,15-0,28µg/µl; frasco; combinación farmaceútica; método para rellenar el frasco; y su uso en asma y/o epoc
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CL2015001469A1 (es) Composiciones de liberación controlada y métodos para su uso
MX2009008769A (es) Formulaciones de proteina que contienen sorbitol.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
AR082688A1 (es) Uso de aglomerantes para preparar formulaciones estables al almacenamiento
HN2012000031A (es) Terapia de combinacion para el tratamiento de la diabetes
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
PA8649901A1 (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
AR089302A1 (es) Un medicamento inhalable
MX2014001621A (es) Composiciones topicas antioxidantes.
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
UA111821C2 (uk) Застосування діатомітової землі як наповнювача у твердих фармацевтичних препаратах
EP3000464A3 (en) Composition comprising farnesol and use thereof
CL2013002353A1 (es) Uso de una composicion farmaceutica que contiene al menos un compuesto que contiene selenita y al menos un acido farmaceuticamente aceptable, util en la preparacion de un medicamento para el tratamiento de alteraciones celulares cervicales que tienen una calificacion pap de pap iii o pap iiid y/o una calificacion cin &gt; o = a cin 1.